• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix launches Phase III trial for eye plug

March 19, 2014 By drugdelivery

Ocular Therapeutix launches Phase III trial for eye plug

Bedford, mass.-based Ocular Therapeutix launched Phase III human clinical studies of its drug-releasing optical plug in patients undergoing cataract surgery.

The company plans to enroll 240 patients in a randomized, double-masked studies evaluating the safety and efficacy of its plugs for sustained-release of the steroid dexamethasone to the surface of the eye for up to 30 days. Ocular hopes to recreate success seen in earlier studies, which reported relief from pain and inflammation in patients treated with the drug-release plugs.

Ocular’s implanted plugs aim to replace traditional eye-drops, which patients often have trouble adhering to. Inconsistent use of the usual topical steroids can lead to persistent post-surgery inflammation and may affect visual outcomes of surgery, the company said.

"A single-dose corticosteroid can help manage issues of compliance by putting dosing into the hands of the physician and avoiding up to 4 drops per day and a tapering regimen which is confusing for the patient," Ocular president & CEO Amar Sawhney said in prepared remarks. "We look forward to the completion of this trial, and continuing on to the second Phase 3 trial later this year."

The proprietary plugs can be tailored to release their drug payload over a set period of time, after which the material is designed to dissolve.

Filed Under: Drug-Device Combinations Tagged With: Clinical Trials, Ocular Therapeutix Inc

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS